Price (90d)
$23.32Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $460.16M | $-175.54M | $-1.60 |
| 2024 | $398.99M | $-257.10M | $-2.60 |
| 2023 | $266.72M | $-334.62M | $-34.60 |
| 2022 | $215.04M | $-443.29M | $-46.30 |
| 2021 | $144.31M | $-704.47M | $-75.80 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-0.55 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.46 vs $-0.68beat
- Thu, May 7$-0.46 vs $-0.53beat
- Thu, Feb 26$-0.46 vs $-0.44miss
- Thu, Nov 6$-0.33 vs $-0.28miss
- Thu, Aug 7$-0.37 vs $-0.37beat
- Thu, May 8$-0.45 vs $-0.50beat
Estimates and results for ZLAB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
ZLABhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsmarketbeat.com·7d ago·Neutral
Zai Lab Q2 Earnings Call Highlights Zai Lab NASDAQ: ZLAB said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a global biopharmaceutical business.
View source ↗